Drugs / EVAX-01-CAF09b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03715985 | Jan 2019 → Dec 2022 | metastatic melanoma, non-small cell lung carcinoma, urothelial carcinoma | Herlev Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVAX-01-CAF09b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03715985 ↗ |
| Modality | Vaccine | “personalized neo-antigen vaccine” NCT03715985 ↗ |